title: PKC 412 FLT3 inhibitor therapy in AML: results of a phase II trial.
authors.affiliation: Dana-Farber Cancer Institute, Boston, MA, USA.
authors.forename: R M
authors.initials: RM
authors.lastname: Stone
authors.forename: J
authors.initials: J
authors.lastname: De Angelo
authors.forename: I
authors.initials: I
authors.lastname: Galinsky
authors.forename: E
authors.initials: E
authors.lastname: Estey
authors.forename: V
authors.initials: V
authors.lastname: Klimek
authors.forename: W
authors.initials: W
authors.lastname: Grandin
authors.forename: D
authors.initials: D
authors.lastname: Lebwohl
authors.forename: A
authors.initials: A
authors.lastname: Yap
authors.forename: P
authors.initials: P
authors.lastname: Cohen
authors.forename: E
authors.initials: E
authors.lastname: Fox
authors.forename: D
authors.initials: D
authors.lastname: Neuberg
authors.forename: J
authors.initials: J
authors.lastname: Clark
authors.forename: D G
authors.initials: DG
authors.lastname: Gilliland
authors.forename: J D
authors.initials: JD
authors.lastname: Griffin
mesh_terms: D001752:Blast Crisis; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000473:pathology; D011493:Protein Kinase C / Q000037:antagonists & inhibitors*; D011518:Proto-Oncogene Proteins / Q000037:antagonists & inhibitors; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D051941:fms-Like Tyrosine Kinase 3
chemical_list: D004791:Enzyme Inhibitors; D011518:Proto-Oncogene Proteins; C497970:FLT3 protein, human; D020794:Receptor Protein-Tyrosine Kinases; D051941:fms-Like Tyrosine Kinase 3; D011493:Protein Kinase C